New developments in the treatment of hepatitis C

Gut

Volumn 52, Issue 5, 2003, Pages 756-757

  Rossi, S J ^a   Wright, T L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTISENSE OLIGONUCLEOTIDE; HISTAMINE DERIVATIVE; LEVOVIRIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAMIDINE; RIBAVIRIN; RIBAVIRIN DERIVATIVE; RIBOZYME; UNCLASSIFIED DRUG; VIRUS RNA;

BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG TARGETING; FEVER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INJECTION SITE; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REGULATORY MECHANISM; RETROSPECTIVE STUDY; REVIEW; RNA REPLICATION; SIDE EFFECT; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE III; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; RIBOFLAVIN;

EID: 0038638950     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.5.756     Document Type: Review

References (10)

1. National Institutes of Health Consensus Development Conference Panel Statement: Management of Hepatitis C. Hepatology 2002:36 (Suppl I).
2. Glue P, Fang J, Rouzier-Panis R, et al. Pegylated interferon-α-2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000;68:556-67.
3. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001;40:539-51.
4. Lindsay K, Trepo C, Heintges T, et al. A randomized double-blind trial comparing pegylated interferon to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
5. Zeuzem S, Feinman V, Basenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.
6. Heathcote J, Shiffmann M, Cooksley G, et al. Peginterferon alfa 2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-80.
7. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-65.
8. Fried MW, Shiffman ML, Reddy RK, et al. Peginterferon alfa-2a (40 KD) in combination with ribavirin: Efficacy and safely results from a phase III, randomized, actively controlled multicenter study. N Engl J Med 2002;347:975-82.
9. Hadziyannis SJ, Morgan TR, Balan V, et al. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C: a randomized study of the effect of treatment duration and ribavirin dose. EASL 2002, Barcelona, Spain, May 2002 (abstract).
10. Locarnini SA, Bartolomeusz A. Advances in hepatitis C: What is coming in the next 5 years? J Gastroenterol Hepatol 2002;17:442-7.